Clinical Trials Logo
  1. Home
  2. Thymoma
  3. NCT04162691
  4. Details
NCT04162691 Clinical Trial

Single Cell Sequencing Analysis of Thymoma

Thymoma Clinical Trial

Official title:
Single Cell Sequencing Analysis of Thymoma

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04162691
Other study ID # SCS-001
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 6, 2020
Est. completion date December 31, 2023

Study information
Verified date January 2023
Source Zhejiang Cancer Hospital
Contact An ZHAO, MD, PHD
Phone 8688122413
Email zhaoan@zjcc.org.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to understand how genetics play a role in thymoma. Intratumoral heterogeneity is among the greatest challenges in precision cancer therapy. However, developments in high-throughput single-cell RNA sequencing (scRNA-seq) may now provide the statistical power to dissect the diverse cellular populations of tumors. This study aims to find out how it affects genetic and protein expression in patients with malignant thymoma, compared to Benign thymoma, at a single-cell level using a flow cytometry and RNA-sequencing protocol.

Recruitment information / eligibility
Status Recruiting
Enrollment 10
Est. completion date December 31, 2023
Est. primary completion date June 1, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients diagnosed with thymoma - Ability to provide written consent and comply with the protocol - At least 18 years of age Exclusion Criteria: - Patients undergoing thymoma treatment - Patients with previous malignancy - Known HIV positive status. - Evidence of abnormality of any immune cell population from a drug-induced or genetic cause.

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• Tissue
Four 4-5 mm tissues of the thymoma

Locations
Country Name City State
China An Zhao Hangzhou

Sponsors (1)
Lead Sponsor Collaborator
Zhejiang Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary Determination of cell population from thymoma The genes expression and the cell population through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT01950572 - Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Terminated NCT00818090 - Paclitaxel and Cisplatin for Thymic Neoplasm Phase 2
Completed NCT00332969 - Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma Phase 2
Completed NCT00921739 - Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies Phase 1
Recruiting NCT05255965 - IL-8+ naïve T Cells as a Biomarker for Thymoma Identification
Withdrawn NCT02948855 - Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases
Completed NCT00387868 - Preoperative Treatment of Patients With High Risk Thymoma Phase 2
Completed NCT01272817 - Nonmyeloablative Allogeneic Transplant N/A
Recruiting NCT03466827 - Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma Phase 2
Completed NCT02220855 - A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas Phase 2
Completed NCT03288662 - Relationship Between Computed Tomography Manifestation and Histopathological Classification of Thymic Epithelial Tumors N/A
Active, not recruiting NCT01242072 - Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies Phase 1
Recruiting NCT06029621 - Robot-assisted vs VATS for Thymoma N/A
Recruiting NCT03921671 - Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT) Phase 2
Recruiting NCT06248515 - A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors Phase 2
Active, not recruiting NCT01621568 - Sunitinib for Advanced Thymus Cancer Following Earlier Treatment Phase 2
Recruiting NCT05262582 - Comparison of Single Port and Two Ports Robotic Assisted Thoracic Surgery for Thymectomy N/A
Terminated NCT01100944 - A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies Phase 1/Phase 2
Active, not recruiting NCT03968315 - An Investigational Scan (MRI) in Imaging Patients With Newly-Diagnosed or Recurrent Thymoma N/A
Recruiting NCT06086327 - Application of 68Ga-Pentixafor PET/CT for Thymoma Early Phase 1